纳武利尤单抗联合伊匹木单抗一线治疗晚期NSCLC的4年随访结果
CheckMate 227第1部分研究在至少4年随访后,纳武利尤单抗联合伊匹木单抗对比化疗在PD-L1≥1%和<1%的晚期NSCLC患者中均持续显示总生存获益,4年OS率分别为29% vs 18%和24% vs 10%,安全性可控,因治疗相关不良事件停药不影响长期获益。
要点
- PD-L1≥1%患者中,双免疫联合对比化疗的4年OS率为29% vs 18%,HR=0.76。
- PD-L1<1%患者中,双免疫联合对比化疗的4年OS率为24% vs 10%,HR=0.64。
- 因治疗相关不良事件停用双免疫联合的患者仍保持长期OS获益。
核心结论
- 至少4年随访后,一线纳武利尤单抗联合伊匹木单抗在晚期NSCLC中持续显示持久长期疗效,未发现新安全性信号。
研究设计与样本
- 随机、开放标签、3期CheckMate 227第1部分试验,成人初治IV期或复发NSCLC按1:1:1随机分组。
主要发现
- 中位随访54.8个月后,PD-L1≥1%患者双免疫联合对比化疗的OS HR=0.76(95%CI 0.65-0.90),4年OS率29% vs 18%。
- PD-L1<1%患者双免疫联合对比化疗的OS HR=0.64(95%CI 0.51-0.81),4年OS率24% vs 10%。
- 鳞癌和非鳞癌组织学类型中均观察到获益。
- 描述性分析中,双免疫联合对比纳武利尤单抗(PD-L1≥1%)和纳武利尤单抗联合化疗(PD-L1<1%)疗效改善。
关键数值与推荐
- 双免疫联合最常见免疫介导不良事件为皮疹;除内分泌事件外,多数免疫介导不良事件发生在治疗开始6个月内并在其后3个月内缓解,主要使用全身性糖皮质激素。
临床怎么用
- 一线纳武利尤单抗联合伊匹木单抗可用于晚期NSCLC患者,PD-L1≥1%和<1%人群均有长期生存获益。
- 免疫介导不良事件发生早且经指南管理可快速缓解,因治疗相关不良事件停药不影响长期获益。
局限性
- PD-L1<1%人群的分析为预设描述性分析,非主要终点。
- 因治疗相关不良事件停药患者的疗效分析为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' follow-up. METHODS: Adults with previously untreated stage IV or recurrent NSCLC were randomized (1:1:1) to nivolumab plus ipilimumab, nivolumab, or chemotherapy (PD-L1 ≥1%); or to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy (PD-L1 <1%). Efficacy included OS and other measures. Safety included timing and management of immune-mediated adverse events (AEs). A post hoc analysis evaluated efficacy in patients who discontinued nivolumab plus ipilimumab due to treatment-related AEs (TRAEs). RESULTS: After 54.8 months' median follow-up, OS remained longer with nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 greater than or equal to 1% (hazard ratio = 0.76; 95% confidence interval: 0.65-0.90) and PD-L1 less than 1% (0.64; 0.51-0.81); 4-year OS rate with nivolumab plus ipilimumab versus chemotherapy was 29% versus 18% (PD-L1 ≥1%); and 24% versus 10% (PD-L1 <1%). Benefits were observed in both squamous and nonsquamous histologies. In a descriptive analysis, efficacy was improved with nivolumab plus ipilimumab relative to nivolumab (PD-L1 ≥1%) and nivolumab plus chemotherapy (PD-L1 <1%). Safety was consistent with previous reports. The most common immune-mediated AE with nivolumab plus ipilimumab, nivolumab, and nivolumab plus chemotherapy was rash; most immune-mediated AEs (except endocrine events) occurred within 6 months from start of treatment and resolved within 3 months after, mainly with systemic corticosteroids. Patients who discontinued nivolumab plus ipilimumab due to TRAEs had long-term OS benefits, as seen in the all randomized population. CONCLUSIONS: At more than 4 years' minimum follow-up, with all patients off immunotherapy treatment for at least 2 years, first-line nivolumab plus ipilimumab continued to demonstrate durable long-term efficacy in patients with advanced NSCLC. No new safety signals were identified. Immune-mediated AEs occurred early and resolved quickly with guideline-based management. Discontinuation of nivolumab plus ipilimumab due to TRAEs did not have a negative impact on the long-term benefits seen in all randomized patients.
引用
- Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2021. PMID: 34648948. doi:10.1016/j.jtho.2021.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。